Your browser doesn't support javascript.
loading
Postoperative Radiation Therapy in Patients with Extracranial Chondrosarcoma: A Joint Study of the French Sarcoma Group and Rare Cancer Network.
Terlizzi, Mario; Le Pechoux, Cécile; Salas, Sébastien; Rapeaud, Etienne; Lerouge, Delphine; Sunyach, Marie P; Vogin, Guillaume; Sole, Claudio V; Zilli, Thomas; Lutsyk, Myroslav; Mampuya, Ange; Calvo, Felipe A; Attal, Justine; Karahissarlian, Vardouhie; De Bari, Berardino; Ozsahin, Mahmut; Baumard, Florian; Krengli, Marco; Gomez-Brouchet, Anne; Sargos, Paul; Rochcongar, Goulven; Bazille, Céline; Roth, Vincent; Salleron, Julia; Thariat, Juliette.
Afiliação
  • Terlizzi M; Department of Radiation Oncology, Institut Bergonie, Bordeaux, France.
  • Le Pechoux C; Institut Gustave Roussy, Villejuif, France.
  • Salas S; Assistance Publique Hôpitaux de Marseille, Timone Hospital, Marseille, France.
  • Rapeaud E; Department of Radiation Oncology, Centre Baclesse/ARCHADE-Normandie Université, Caen, France.
  • Lerouge D; Department of Radiation Oncology, Centre Baclesse/ARCHADE-Normandie Université, Caen, France.
  • Sunyach MP; Centre Léon Berard, Lyon, France.
  • Vogin G; Institut de Cancérologie de Lorraine, Vandoeuvre Les Nancy, France.
  • Sole CV; Clinica Instituto de Radiomedicina (IRAM) and Facultad de Medicina, Universidad Diego Portales, Santiago, Chile; Facultad de Medicina, Universidad Diego Portales, Santiago, Chile.
  • Zilli T; Radiation Oncology, Geneva University Hospital, Geneva, Switzerland.
  • Lutsyk M; Rambam HCC, Haïfa, Israel.
  • Mampuya A; Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
  • Calvo FA; Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Attal J; IUCT-Oncopole, Toulouse, France.
  • Karahissarlian V; Centre Léon Berard, Lyon, France.
  • De Bari B; Centre Hospitalier Régional Universitaire "Jean Minjoz," Université de Bourgogne-Franche Comté, Besançon, France.
  • Ozsahin M; Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
  • Baumard F; Department of Biostatistics, Institut de Cancérologie de Lorraine, Université de Lorraine, Vandœuvre-lès-Nancy, France.
  • Krengli M; Department of Radiation Oncology, University Hospital, Novara, Italy.
  • Gomez-Brouchet A; Department of Pathology, University Hospital of Toulouse, Toulouse, France.
  • Sargos P; Department of Radiation Oncology, Institut Bergonie, Bordeaux, France.
  • Rochcongar G; Department of Orthopedics, University Hospital of Caen, Caen, France.
  • Bazille C; Department of Pathology, University Hospital of Caen, Caen, France.
  • Roth V; Easy-CRF SAS, Mathieu, France.
  • Salleron J; Department of Biostatistics, Institut de Cancérologie de Lorraine, Université de Lorraine, Vandœuvre-lès-Nancy, France.
  • Thariat J; Department of Radiation Oncology, Centre Baclesse/ARCHADE-Normandie Université, Caen, France; Laboratoire de Physique Corpusculaire, Caen, France; Unicaen-Normandie Université, Caen, France. Electronic address: jthariat@gmail.com.
Int J Radiat Oncol Biol Phys ; 107(4): 726-735, 2020 07 15.
Article em En | MEDLINE | ID: mdl-32289473
ABSTRACT

PURPOSE:

Postoperative radiation therapy (poRT) of intracranial/skull base chondrosarcomas (CHSs) is standard treatment. However, consensus is lacking for poRT in extracranial CHS (eCHS) owing to their easier resectability and intrinsic radioresistance. We assessed the practice and efficacy of poRT in eCHS. METHODS AND MATERIALS This multicentric retrospective study of the French Sarcoma Group/Rare Cancer Network included patients with eCHS who were operated on between 1985 and 2015. Inverse propensity score weighting (IPTW) was used to minimize poRT allocation biases.

RESULTS:

Of 182 patients, 60.4% had bone and 39.6% had soft-tissue eCHS. eCHS were of conventional (31.9%), myxoid (28.6%; 41 extraskeletal, 11 skeletal), mesenchymal (9.9%), or other subtypes. En-bloc surgery with complete resection was performed in 52.6% and poRT in 36.8% of patients (median dose, 54 Gy). Irradiated patients had unfavorable initial characteristics, with higher grade and incomplete resection. Median follow-up time was 61 months. Five-year incidence of local relapse was 10% with poRT versus 21.6% without (P = .050). Using the IPTW method, poRT reduced the local relapse risk (hazard ratio, 0.27; 95% confidence interval, 0.14-0.52; P < .001). Five-year disease-free survival (DFS) was 71.8% with poRT and 64.2% without (P = .680). Using the IPTW method, poRT improved DFS (hazard ratio, 0.51; 95% confidence interval, 0.30-0.85; P = .010). The benefit of poRT on local relapse and DFS was confirmed after exclusion of the extraskeletal subtype. There was no difference in overall survival. Prognostic factors of poorer DFS in multivariate analysis were deeper location, higher grade, incomplete resection, and no poRT.

CONCLUSIONS:

poRT should be offered in patients with eCHS and high-grade or incomplete resection, regardless of the histologic subtype.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ósseas / Condrossarcoma Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ósseas / Condrossarcoma Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article